CELS Valley Ready Program Investor/Mentor RSVP
Thank you for your interest in joining us for the CELS Valley Ready (VR) Program!
We’re excited to invite you to participate as an investor or mentor during the upcoming Investor/Mentor Meetings on Thursday, November 13, 2025 | 9:00 AM - 12:00 PM.
The Valley Ready (VR) program provides an exclusive opportunity to engage directly with high-potential Canadian life sciences companies as they prepare to scale into the U.S. market. Designed for health science scale-ups that have completed a Pre-Seed or Seed round, the program immerses founders in the dynamic Bay Area ecosystem, connecting them with top investors, mentors, and industry experts.
Your insights and feedback play a vital role in helping these founders refine their strategies and accelerate growth.
Kindly complete the form below to RSVP and indicate your interest and availability. A calendar invitation will be shared with you
Companies Presenting:
ReWire Dtx is a digital therapeutics startup developing neuroscience-based mobile tools to treat chronic depression and other behavioral health conditions. Their flagship product, Odessa Dtx, delivers personalized, non-pharmaceutical interventions using an FDA-cleared neural assessment to tailor therapy in real time. ReWire is preparing for a $1.1M USD pre-seed raise.
Tarkka Manufacturing Solutions Inc.
Tarkka is revolutionizing mobility care with Tetrx™, a system that enables same-day fitting and delivery of pressure-relieving mobility solutions, cutting months-long processes down to minutes and reducing burden across the healthcare ecosystem. With strong customer interest they are closing a $500K SAFE.
Integrated NanoTherapeutics is a preclinical biotech company developing a lipid nanoparticle (LNP) platform for autoimmune diseases, with a lead immunotherapy candidate targeting Type 1 Diabetes and broader applications across inflammatory conditions. INT is looking to secure a lead investor for their $35M USD Series A round, which they already have half soft circled.
Qualisure Diagnostics uses AI and proprietary algorithms to flag non-adherent patients and protocol violations during clinical trials, enhancing trial quality, reducing costs, and improving accuracy for oncology and rare disease studies. Qualisure is preparing for a $7M USD raise to expand the commercial team and accelerate adoption.
Kare Technologies is developing sustainable, patent-protected processes to synthesize cannabinoid-based therapeutics from sources like orange peels, enabling novel CBD and THC analogs with reduced psychoactive effects. Their platform aims to deliver safer treatments for epilepsy, chronic pain, and metabolic diseases while generating licensing revenue and advancing toward a $5M Series A to reach IND readiness.
Aufero Medical develops a medical device add-on accessory that provides on-demand catheter contact stability for electrophysiology ablation procedures, improving precision and reducing arrhythmia recurrence risk.
NovusTX Devices is developing a groundbreaking focused ultrasound neurostimulation platform to treat Parkinson’s disease and essential tremor.